Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy

Next Previous
Trial Profile

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Firicabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms FIRCE-1
  • Sponsors CARGO Therapeutics

Most Recent Events

  • 31 Jan 2025 According to Cargo media release, company to discontinue this study. Decision of company is based on the number of adverse events suffered by patients, combined with the fact that "the data generated so far does not meet our expectations of a competitive benefit-risk profile for patients in the context of available treatment options.
  • 29 Jan 2025 Status changed from recruiting to discontinued.
  • 04 Jun 2024 Study design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top